Zefylti will be available as 30 MU/0.5 mL and 48 MU/0.5 mL and is intended for the treatment of neutropenia and the mobilisation of peripheral progenitor cells
The approved product has an estimated market size of US$ 106 million for the twelve months ending October 2024, according to IQVIA
He did Master’s of Pharmacy (Pharmaceutical Technology, Formulations) from National Institute of Pharmaceutical Education and Research, Mohali and Bachelor of Pharmacy from Osmania University
The GMP inspection assessed mammalian and microbial drug substance manufacturing facility sections
Growth markets revenue increased by 44 YoY to Rs. 812 crore
USFDA completes PAI of Lupin’s biotech facility in Pune
The product is expected to be launched in Q3FY25
The sANDA was submitted as “Prior Approval Supplement” for addition of an alternate drug product manufacturing, labeling, packaging, and testing facility
Revenue from Operations increased by 10.5% YoY to Rs. 7,567 crore with growth across the businesses
The approved product has an estimated market size of US$ 268 million for the twelve months ending June 2024, according to IQVIA
Subscribe To Our Newsletter & Stay Updated
